nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CREB1—FSH signaling pathway—CGA—conduct disorder	0.0852	0.0852	CbGpPWpGaD
Naloxone—CREB1—TSH signaling pathway—CGA—conduct disorder	0.0417	0.0417	CbGpPWpGaD
Naloxone—CREB1—Hypothetical Network for Drug Addiction—DRD4—conduct disorder	0.0416	0.0416	CbGpPWpGaD
Naloxone—CREB1—Glucocorticoid receptor regulatory network—CGA—conduct disorder	0.035	0.035	CbGpPWpGaD
Naloxone—CREB1—NOTCH2 intracellular domain regulates transcription—EP300—conduct disorder	0.0316	0.0316	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—MB21D1—conduct disorder	0.0273	0.0273	CbGpPWpGaD
Naloxone—CREB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA2—conduct disorder	0.0214	0.0214	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—POLR3A—conduct disorder	0.0201	0.0201	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—WASF1—conduct disorder	0.0169	0.0169	CbGpPWpGaD
Naloxone—CREB1—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.0161	0.0161	CbGpPWpGaD
Naloxone—TLR4—Immune System—MB21D1—conduct disorder	0.0159	0.0159	CbGpPWpGaD
Naloxone—CREB1—Signaling by NOTCH2—EP300—conduct disorder	0.0148	0.0148	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0125	0.0125	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—GABRA2—conduct disorder	0.0123	0.0123	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.012	0.012	CbGpPWpGaD
Naloxone—TLR4—Immune System—POLR3A—conduct disorder	0.0117	0.0117	CbGpPWpGaD
Naloxone—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.0114	0.0114	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0105	0.0105	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—SLC6A4—conduct disorder	0.0102	0.0102	CbGpPWpGaD
Naloxone—TLR4—Immune System—WASF1—conduct disorder	0.00983	0.00983	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—DRD4—conduct disorder	0.00958	0.00958	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—MB21D1—conduct disorder	0.00954	0.00954	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00939	0.00939	CbGpPWpGaD
Naloxone—CREB1—Circadian Clock—EP300—conduct disorder	0.00933	0.00933	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CGA—conduct disorder	0.00911	0.00911	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00886	0.00886	CbGpPWpGaD
Naloxone—CREB1—ATF-2 transcription factor network—EP300—conduct disorder	0.00882	0.00882	CbGpPWpGaD
Naloxone—OPRD1—G alpha (i) signalling events—DRD4—conduct disorder	0.00842	0.00842	CbGpPWpGaD
Naloxone—CREB1—Validated targets of C-MYC transcriptional repression—EP300—conduct disorder	0.00837	0.00837	CbGpPWpGaD
Naloxone—CREB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00807	0.00807	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CGA—conduct disorder	0.00799	0.00799	CbGpPWpGaD
Naloxone—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00782	0.00782	CbGpPWpGaD
Naloxone—CREB1—Transmission across Chemical Synapses—COMT—conduct disorder	0.00775	0.00775	CbGpPWpGaD
Naloxone—CREB1—AP-1 transcription factor network—EP300—conduct disorder	0.0077	0.0077	CbGpPWpGaD
Naloxone—CREB1—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00769	0.00769	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00765	0.00765	CbGpPWpGaD
Naloxone—ESR1—FOXM1 transcription factor network—EP300—conduct disorder	0.00759	0.00759	CbGpPWpGaD
Naloxone—OPRK1—G alpha (i) signalling events—DRD4—conduct disorder	0.00739	0.00739	CbGpPWpGaD
Naloxone—ESR1—FOXA1 transcription factor network—EP300—conduct disorder	0.00731	0.00731	CbGpPWpGaD
Naloxone—ESR1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00705	0.00705	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—POLR3A—conduct disorder	0.007	0.007	CbGpPWpGaD
Naloxone—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00685	0.00685	CbGpPWpGaD
Naloxone—CREB1—Regulation of nuclear SMAD2/3 signaling—EP300—conduct disorder	0.00685	0.00685	CbGpPWpGaD
Naloxone—CREB1—Glucocorticoid receptor regulatory network—EP300—conduct disorder	0.00678	0.00678	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CGA—conduct disorder	0.00675	0.00675	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0067	0.0067	CbGpPWpGaD
Naloxone—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0065	0.0065	CbGpPWpGaD
Naloxone—CREB1—Androgen receptor signaling pathway—EP300—conduct disorder	0.00635	0.00635	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—DRD4—conduct disorder	0.00624	0.00624	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00602	0.00602	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—COMT—conduct disorder	0.00594	0.00594	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00592	0.00592	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—MAOA—conduct disorder	0.0059	0.0059	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—WASF1—conduct disorder	0.00589	0.00589	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00587	0.00587	CbGpPWpGaD
Naloxone—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00579	0.00579	CbGpPWpGaD
Naloxone—ESR1—ATF-2 transcription factor network—EP300—conduct disorder	0.00578	0.00578	CbGpPWpGaD
Naloxone—CREB1—Immune System—MB21D1—conduct disorder	0.00556	0.00556	CbGpPWpGaD
Naloxone—ESR1—Validated nuclear estrogen receptor alpha network—EP300—conduct disorder	0.00542	0.00542	CbGpPWpGaD
Naloxone—CREB1—Signaling by NOTCH—EP300—conduct disorder	0.0054	0.0054	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00537	0.00537	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CGA—conduct disorder	0.00515	0.00515	CbGpPWpGaD
Naloxone—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0051	0.0051	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—DRD4—conduct disorder	0.0051	0.0051	CbGpPWpGaD
Naloxone—ESR1—AP-1 transcription factor network—EP300—conduct disorder	0.00504	0.00504	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00496	0.00496	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CGA—conduct disorder	0.00469	0.00469	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CGA—conduct disorder	0.00467	0.00467	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CGA—conduct disorder	0.00451	0.00451	CbGpPWpGaD
Naloxone—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—conduct disorder	0.00449	0.00449	CbGpPWpGaD
Naloxone—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00447	0.00447	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—DRD4—conduct disorder	0.00447	0.00447	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00437	0.00437	CbGpPWpGaD
Naloxone—CREB1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00416	0.00416	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CGA—conduct disorder	0.0041	0.0041	CbGpPWpGaD
Naloxone—CREB1—Immune System—POLR3A—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—EP300—conduct disorder	0.00408	0.00408	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00405	0.00405	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00383	0.00383	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CGA—conduct disorder	0.00381	0.00381	CbGpPWpGaD
Naloxone—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00378	0.00378	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—DRD4—conduct disorder	0.00378	0.00378	CbGpPWpGaD
Naloxone—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00349	0.00349	CbGpPWpGaD
Naloxone—CYP2C8—Biological oxidations—COMT—conduct disorder	0.00348	0.00348	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CGA—conduct disorder	0.00346	0.00346	CbGpPWpGaD
Naloxone—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.00345	0.00345	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00345	0.00345	CbGpPWpGaD
Naloxone—CREB1—Immune System—WASF1—conduct disorder	0.00343	0.00343	CbGpPWpGaD
Naloxone—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.00343	0.00343	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—HTR2A—conduct disorder	0.00333	0.00333	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—EP300—conduct disorder	0.00331	0.00331	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00324	0.00324	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00296	0.00296	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00294	0.00294	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—HTR2A—conduct disorder	0.00292	0.00292	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—DRD4—conduct disorder	0.00288	0.00288	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.0028	0.0028	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CGA—conduct disorder	0.00277	0.00277	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CGA—conduct disorder	0.00276	0.00276	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00273	0.00273	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CGA—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—POLR3A—conduct disorder	0.00266	0.00266	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—DRD4—conduct disorder	0.00263	0.00263	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00262	0.00262	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—DRD4—conduct disorder	0.00262	0.00262	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—DRD4—conduct disorder	0.00253	0.00253	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00247	0.00247	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CGA—conduct disorder	0.00242	0.00242	CbGpPWpGaD
Naloxone—TLR4—Immune System—EP300—conduct disorder	0.00238	0.00238	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.0023	0.0023	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—DRD4—conduct disorder	0.00229	0.00229	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00226	0.00226	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—WASF1—conduct disorder	0.00222	0.00222	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—WASF1—conduct disorder	0.00221	0.00221	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00214	0.00214	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CGA—conduct disorder	0.00205	0.00205	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—WASF1—conduct disorder	0.00194	0.00194	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—DRD4—conduct disorder	0.00194	0.00194	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—HTR2A—conduct disorder	0.00188	0.00188	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00187	0.00187	CbGpPWpGaD
Naloxone—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00185	0.00185	CbGpPWpGaD
Naloxone—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00184	0.00184	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CGA—conduct disorder	0.00181	0.00181	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HTR2A—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HTR2A—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—HTR2A—conduct disorder	0.00165	0.00165	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—WASF1—conduct disorder	0.00164	0.00164	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EP300—conduct disorder	0.00161	0.00161	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—DRD4—conduct disorder	0.00155	0.00155	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—DRD4—conduct disorder	0.00155	0.00155	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HTR2A—conduct disorder	0.0015	0.0015	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—WASF1—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—EP300—conduct disorder	0.00142	0.00142	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.00139	0.00139	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—DRD4—conduct disorder	0.00136	0.00136	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CGA—conduct disorder	0.00132	0.00132	CbGpPWpGaD
Naloxone—ALB—Metabolism—CGA—conduct disorder	0.00131	0.00131	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00127	0.00127	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—COMT—conduct disorder	0.00121	0.00121	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MAOA—conduct disorder	0.0012	0.0012	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00119	0.00119	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CGA—conduct disorder	0.00115	0.00115	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—DRD4—conduct disorder	0.00115	0.00115	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—DRD4—conduct disorder	0.00102	0.00102	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HTR2A—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HTR2A—conduct disorder	0.00101	0.00101	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR2A—conduct disorder	0.000885	0.000885	CbGpPWpGaD
Naloxone—CREB1—Immune System—EP300—conduct disorder	0.000829	0.000829	CbGpPWpGaD
Naloxone—CREB1—Disease—EP300—conduct disorder	0.000766	0.000766	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR2A—conduct disorder	0.000748	0.000748	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CGA—conduct disorder	0.000707	0.000707	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR2A—conduct disorder	0.000663	0.000663	CbGpPWpGaD
Naloxone—ALB—Hemostasis—EP300—conduct disorder	0.000625	0.000625	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—COMT—conduct disorder	0.000595	0.000595	CbGpPWpGaD
Naloxone—ALB—Metabolism—COMT—conduct disorder	0.000591	0.000591	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MAOA—conduct disorder	0.000591	0.000591	CbGpPWpGaD
Naloxone—ALB—Metabolism—MAOA—conduct disorder	0.000587	0.000587	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000573	0.000573	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000569	0.000569	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EP300—conduct disorder	0.000536	0.000536	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EP300—conduct disorder	0.000534	0.000534	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—EP300—conduct disorder	0.000519	0.000519	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—COMT—conduct disorder	0.000518	0.000518	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MAOA—conduct disorder	0.000514	0.000514	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EP300—conduct disorder	0.000469	0.000469	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EP300—conduct disorder	0.000396	0.000396	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EP300—conduct disorder	0.000351	0.000351	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—COMT—conduct disorder	0.000319	0.000319	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MAOA—conduct disorder	0.000317	0.000317	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—EP300—conduct disorder	0.000255	0.000255	CbGpPWpGaD
Naloxone—ALB—Metabolism—EP300—conduct disorder	0.000254	0.000254	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—EP300—conduct disorder	0.000222	0.000222	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—EP300—conduct disorder	0.000137	0.000137	CbGpPWpGaD
